Positron emission tomography (PET) has become widely used for cardiac disease and several cancers. New sensitive antigen-specific tracers are further extending PET usefulness in other settings, including prostate cancer and Alzheimer’s disease (AD).
Deep brain stimulation, pulsed stimulation and wearable tremor-control devices... see how medical devices are transforming the treatment of central nervous system & psychiatric disorders.
Pharma’s use of artificial intelligence and machine learning is growing quickly. How and when should these tools be incorporated? We explore applications in target identification, drug discovery and optimization, clinical trials, manufacturing & commercialization.
This year will see the formation of a new EU health program to strengthen the framework for ongoing coordination between states on measures aimed at disease protection, prevention, preparedness & response.
In our second post exploring trends we expect in the biotech and pharmaceutical development world in 2021, we take a look at digital health, the continuing impact of COVID-19, and growth in pharma investment.
With flu season rapidly approaching, concerns are growing about the risks of a double coronavirus-influenza pandemic that could further overwhelm hospitals and other health care resources.
Hunter Syndrome has attracted a lot of interest from pharma, with trial therapies ranging from enzyme replacement and engineered drugs to gene and cell therapy approaches.
AI is making strides in cardiology, helping to enable quicker assessment & treatment of strokes, faster nuclear imaging & diagnostic radiology, and earlier detection & monitoring of heart disease.
Researchers are looking to map and describe the workings of the tumor immune environment to find ways to potentiate an immune response or counteract immunosuppressive signals.